The company has on Tuesday acquired Yutopar, a widely studied product in the gynaecology segment, from the Solvay Pharmaceuticals of the Netherlands. The company is also planning to extend its portfolio to the other two major speciality therapeutic segments: cardiology and diabetology. Rajkumar Baheti, director (finance), Alembic Pharmaceuticals, said,
